June 9th 2025
In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).
An Economic Path Forward: Thoughts on an Industry Inflection Point
March 3rd 2022The life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.